

RESEARCH ARTICLE

A genetic screen in rodent malaria parasites identifies five new apicoplast putative membrane transporters, one of which is essential in human malaria parasites

Claire P. Sayers  | Vanessa Mollard  | Hayley D. Buchanan  | Geoffrey I. McFadden*  | Christopher D. Goodman* 

School of BioSciences, University of Melbourne, Parkville, Victoria, Australia

Correspondence

Christopher D. Goodman, School of BioSciences, University of Melbourne, Parkville, Victoria, Australia.
Email: deang@unimelb.edu.au

Present Address

Claire P. Sayers, Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

Funding information

Australian Research Council Discovery Project, Grant/Award Number: DP160104980; National Health and Medical Research Council Program and Project Grant, Grant/Award Number: 637406 and 1106213

Abstract

The malaria-causing parasite, *Plasmodium*, contains a unique non-photosynthetic plastid known as the apicoplast. The apicoplast is an essential organelle bound by four membranes. Although membrane transporters are attractive drug targets, only two transporters have been characterised in the malaria parasite apicoplast membranes. We selected 27 candidate apicoplast membrane proteins, 20 of which are annotated as putative membrane transporters, and performed a genetic screen in *Plasmodium berghei* to determine blood stage essentiality and subcellular localisation. Eight apparently essential blood stage genes were identified, three of which were apicoplast-localised: *PbANKA_0614600* (DMT2), *PbANKA_0401200* (ABCB4), and *PbANKA_0505500*. Nineteen candidates could be deleted at the blood stage, four of which were apicoplast-localised. Interestingly, three apicoplast-localised candidates lack a canonical apicoplast targeting signal but do contain conserved N-terminal tyrosines with likely roles in targeting. An inducible knockdown of an essential apicoplast putative membrane transporter, *PfDMT2*, was only viable when supplemented with isopentenyl diphosphate. Knockdown of *PfDMT2* resulted in loss of the apicoplast, identifying *PfDMT2* as a crucial apicoplast putative membrane transporter and a candidate for therapeutic intervention.

KEYWORDS

apicoplast, genetic screen, isopentenyl diphosphate (IPP), knockdown, knockout (KO), localise, membrane transporter, *Plasmodium*

1 | INTRODUCTION

Membrane transporters are ideal malaria drug targets as the *Plasmodium* parasite is typically reliant on them to establish an infection within host cells, scavenge from the environment, and shuffle resources between intracellular compartments. Many membrane transporters are vulnerable to pharmacological agents and used in the treatment of human disease (Kirk, 2004; Kirk & Lehane, 2014). Furthermore, a number of *Plasmodium* transporters are attractive molecular targets for drug design, particularly the hexose transporter (Joët, Eckstein-Ludwig, Morin, & Krishna, 2003; Joët & Krishna, 2004; Krishna, Woodrow, Burchmore, Saliba, & Kirk, 2000; Woodrow, Penny, & Krishna, 1999). More recently, both *PfATP4* and *PfFNT* have

emerged as promising drug targets (Golldack et al., 2017; Lehane, Ridgway, Baker, & Kirk, 2014; Marchetti et al., 2015; Rottmann et al., 2010; Spillman et al., 2013). The *Plasmodium* transportome is a vital area of research that will aid our general understanding of malaria parasite biology and ultimately offer novel drug targets to fight the disease.

Detailed sequence analysis identified over 100 membrane transport proteins in the *Plasmodium falciparum* genome (Martin, Ginsburg, & Kirk, 2009; Martin, Henry, Abbey, Clements, & Kirk, 2005). These putative membrane transporters contain multiple hydrophobic transmembrane domains (TMDs) connected by hydrophilic loops, with many having eight to 14 TMDs (Martin et al., 2009). Although this analysis substantially expanded the list of *Plasmodium* transporters, the malaria parasite genome is still considered to be minimalistic in terms of transporter abundance, with just over 2% of the genome

*These authors contributed equally.

encoding transport proteins (Martin et al., 2005). This should therefore result in a low level of redundancy amongst *Plasmodium* transporters relative to the transportomes of other organisms (Martin et al., 2005).

Kenthirapalan, Waters, Matuschewski, and Kooij (2016) reported a genetic screen of 35 putative membrane transporters in *Plasmodium berghei*. During the disease causing blood stage of infection, 17.14% of these putative membrane transporters were found to have essential functions, 11.43% were required for normal growth, and 71.43% could be deleted with no growth defect or arrest across the life cycle (Kenthirapalan et al., 2016). However, of the genes that could be deleted in the blood stage, 45% were found essential for completion of the life cycle, 31% were later required for normal growth, and only 24% were not needed for normal growth throughout the entire life cycle (Kenthirapalan et al., 2016). More recently, Bushell et al. (2017) found that of the 79 transporters targeted for genetic deletion in blood stage *P. berghei* parasites, 33% were essential, 24% were necessary for normal growth, and 43% were dispensable. This may indicate that many membrane transporters have vital roles beyond the blood stage. Subcellular co-localisations were not provided in these studies, making it difficult to link any deletion effects with possible function within the cell.

A primary feature in eukaryotic cells is the compartmentalisation of function into various membrane bound organelles with different internal environments. Membrane transporters are essential for the function and maintenance of organelles as they regulate the movement of molecules across otherwise impermeable membranes. One of the most intriguing organelles in *Plasmodium* is the apicoplast (McFadden, Reith, Munholland, & Lang-Unnasch, 1996). Derived from an algal chloroplast, the apicoplast contains many bacterial and plant-like pathways that are attractive drug targets because they differ markedly from pathways found in humans (McFadden & van Dooren, 2004; Ralph et al., 2004). In the red blood cell stages, the only essential function of the apicoplast is the production of isopentenyl diphosphate (IPP; Yeh & DeRisi, 2011). In *in vitro* culture, genes essential for apicoplast function, and even the entire apicoplast, can be deleted as long as the parasites are provided with a source of IPP (Gisselberg, Dellibovi-Ragheb, Matthews, Bosch, & Prigge, 2013; Yeh & DeRisi, 2011). This is not true for the mosquito and liver stages of the parasite life cycle, where other apicoplast metabolic pathways are essential (Ke et al., 2014; Nagaraj et al., 2013; Rathnapala, Goodman, & McFadden, 2017; van Schaijk et al., 2014; Yu et al., 2008).

To maintain apicoplast metabolism, and thus ensure parasite survival, one or more of the apicoplast membranes must act as a selective molecular barrier. Canonical plant plastids (chloroplasts) have two membranes. The inner membrane contains a number of active transporters, and the outer membrane contains selective channels (Bölter & Soll, 2001; Fischer, 2011; Pick & Weber, 2014). Four membranes surround the apicoplast as a result of its secondary endosymbiotic origins (Köhler et al., 1997; van Dooren & Striepen, 2013). The outer apicoplast membrane is intermittently continuous with the parasite endomembrane system, and the second outermost "periplastid" membrane is derived from the red algal plasma membrane (van Dooren & Striepen, 2013). The two innermost membranes of the apicoplast are homologous to the two membranes of the primary plastids of red algae and plants (McFadden & van Dooren, 2004; van Dooren & Striepen,

2013). Little is known about the distribution of membrane transport processes across these four membranes and how apicoplast transporters interact to import molecules required to fuel apicoplast metabolism and export metabolites to the rest of the parasite.

Mullin et al. (2006) characterised the first apicoplast membrane transporters, the inner and outer triose phosphate transporters, *PfiTPT* and *PfoTPT*, which are homologues of plant plastidic phosphate translocators (Weber & Linka, 2011). A bipartite leader sequence targets *PfiTPT* to the innermost apicoplast membrane, whereas *PfoTPT*, which lacks a targeting leader, localises to the outermost apicoplast membrane (Mullin et al., 2006). The plastidic phosphate translocators of *Plasmodium* were later found to fuel apicoplast metabolism by importing phosphoenolpyruvate, dihydroxyacetone, and 3-phosphoglycerate from parasite glycolysis in the cytosol (Brooks et al., 2010; Lim, Linka, Mullin, Weber, & McFadden, 2010). Banerjee, Jaijyan, Surolia, Singh, and Surolia (2012) reported that during the blood stage of infection of the rodent malaria parasite, *P. berghei*, *PboTPT* was essential and *PbiTPT* was dispensable. However, *PbiTPT* KO parasites displayed growth defects in the mosquito and liver stages (Banerjee et al., 2012). It was suggested that *PboTPT* can transport the *PbiTPT* substrate in blood stage parasites and that the two transporters might not work in tandem (Banerjee et al., 2012). To date, the TPTs remain the only membrane transporters known to be localised to the apicoplast.

Here, we describe a medium throughput genetic screen for apicoplast membrane transporters in *P. berghei*. Candidate apicoplast membrane proteins, many of which are putative membrane transporters, were identified and then investigated using the *Plasmo*GEM vectors (Gomes et al., 2015; Pfander et al., 2011; Pfander, Anar, Brochet, Rayner, & Billker, 2012; Schwach et al., 2015). In *P. berghei*, we localised these candidates by gene tagging and determined essentiality in the blood stage by gene knockout (KO) attempts. Gene knockdowns were performed for two apparently essential apicoplast putative membrane transporters in *P. falciparum*, and IPP supplementation was used to investigate the roles of one in apicoplast biogenesis.

2 | RESULTS

2.1 | Candidate apicoplast membrane transporters

We compiled a list of potential *Plasmodium* apicoplast membrane transporters (Table 1) from two sources: *P. falciparum* putative membrane transporters belonging to known transport families (Martin et al., 2005) and selected members of the predicted *P. falciparum* apicoplast proteome with multiple TMDs (Ralph et al., 2004). Many *P. falciparum* membrane transporters have seven or more TMDs, whereas some have six or fewer (Martin et al., 2005). Without biological data to confirm membrane transport activity, we selected candidate proteins predicted to have at least six TMDs (Table 1). Although multiple TMDs is a minimum requirement of most membrane transporters, some of these proteins may be integral membrane proteins with other functions, in which case further investigation is required.

The first 10 candidates in Table 1 are predicted to be apicoplast-localised; the remaining 17 apparently lack apicoplast targeting signals

TABLE 1 Candidate apicoplast membrane proteins in *Plasmodium*

Gene ID		Annotation	Orthologues				TMD ^b	Predicted targeting ^b			Blood stage expression ^b			Results		
<i>Plasmodium berghei</i>	<i>Plasmodium falciparum</i>		<i>Toxoplasma gondii</i>	<i>Theileria</i>	<i>Babesia</i>	<i>Cryptosporidium</i>		PlasmoAP (signal, transit)	PATS	R	T	S	G	Localisation	Blood stage essentiality	Category
PbANKA_0809500	Pf3D7_0908100	Conserved <i>Plasmodium</i> protein, unknown function	-	-	-	-	10	[+, +]	0.97				Apicoplast	Non-essential ^d		
PbANKA_0803500	Pf3D7_1145500	ABC transporter B family member 3, putative (ABC3 or MDR3)	-	-	-	-	6/7	[+, +]	0.95				Apicoplast*	Non-essential ^d		
PbANKA_1429300	Pf3D7_1213500	Integral membrane protein GPR180, putative	-	-	-	+	7/8	[+, +]	0.94				ND	Essential ^d		
PbANKA_0107700	Pf3D7_0609100	Zinc transporter ZIP1 (ZIP1)	+	+	-	+	8	[+, +]	0.91				Non-apicoplast	Essential ^d		
PbANKA_0505500	Pf3D7_1021300	Conserved <i>Plasmodium</i> protein, unknown function	-	-	-	-	7	[+, +]	1.00				Apicoplast	Essential		
PbANKA_0401200	Pf3D7_0302600	ABC transporter B family member 4, putative (ABC4 or MDR4)	+	-	-	-	6	[+, +]	0.99				Apicoplast	Essential ^{RA}		
PbANKA_0942100	Pf3D7_1104800	Metabolite/drug transporter, putative	+	-	-	+	9	[-, +]	0.93				ND	Essential ^d		
PbANKA_0614600	Pf3D7_0716900	Drug/metabolite transporter, putative (DMT2)	+	+	+	-	9	[+, -]	0.82				Apicoplast*	Essential ^{dv}		
PbANKA_1008700	Pf3D7_1436100	Conserved <i>Plasmodium</i> protein, unknown function	-	+	-	+	5/13	[-, -]	0.98				ND	Non-essential ^d		
PbANKA_0417100	Pf3D7_0904300	Conserved protein, unknown function	-	-	-	-	11/17	[+, +]	0.76				ND	Non-essential ^d		
PbANKA_1103600	Pf3D7_0504000	Cation transporting P-ATPase, putative (ATP3 or ATPase3)	-	+	+	+	12/14	[0, +]	0.25				Apicoplast	Non-essential ^d		
PbANKA_0211900	Pf3D7_0727800	Cation transporting ATPase, putative	-	+	+	+	12/13	[-, +]	0.11				ND	Essential ^d		
PbANKA_1364800	Pf3D7_1352100	ABC transporter B family member 6, putative (ABC6 or MDR6)	-	-	-	-	5/6	[-, +]	0.04				ND	Non-essential ^{SA}		
PbANKA_0208300	Pf3D7_0104800	Novel putative transporter 1 (NPT1)	+	+	+	+	12	[-, +]	0.03				Non-apicoplast	Non-essential ^{dv}		
PbANKA_1446100	Pf3D7_1231400	Amino acid transporter, putative	-	-	-	-	9/10	[-, +]	0.02				ND	Non-essential ^d	Very low	
PbANKA_0311600	Pf3D7_0214800	Conserved <i>Plasmodium</i> protein, unknown function	-	-	-	-	11/10	[-, +]	0.03				Non-apicoplast	Essential ^d	Low	
PbANKA_0802400	Pf3D7_1203400	Major facilitator superfamily domain-containing protein, putative (MFS4)	-	-	-	-	12	[0, -]	0.03				ND	Non-essential ^{dv}	Moderate	
PbANKA_0817000	Pf3D7_0916000	Major facilitator superfamily domain-containing protein, putative (MFS2)	+	+	+	+	11/13	[-, +]	0.02				Non-apicoplast	Non-essential ^{dv}	High	
PbANKA_0410500	Pf3D7_0312500	Major facilitator superfamily-related transporter, putative (MFR3)	-	-	-	-	12/11	[0, -]	0.18				Non-apicoplast	Non-essential ^{dv}	Very high	
PbANKA_1231300	Pf3D7_0516500	Major facilitator superfamily domain-containing protein, putative (MFS1)	+	-	-	-	10/11	[-, -]	0.02				ND	Non-essential ^d		
PbANKA_1115100	Pf3D7_0515500	Amino acid transporter, putative	-	-	-	-	14/15	[-, -]	0.02				ND	Non-essential ^d		
PbANKA_0112500	Pf3D7_0614300	Major facilitator superfamily-related transporter, putative (MFR1)	-	-	-	-	12	[-, -]	0.02				Non-apicoplast	Non-essential ^{dv}	Essential	
PbANKA_1304700	Pf3D7_1440800	Major facilitator superfamily domain-containing protein, putative (MFS6)	-	-	-	-	12	[-, -]	0.02				Apicoplast	Non-essential ^d	Apicoplast/Essential	
PbANKA_0916000	Pf3D7_1132400	Conserved <i>Plasmodium</i> protein, unknown function	-	-	-	-	10/9	[-, -]	0.02				Non-apicoplast	Non-essential ^d	Apicoplast/Non-essential	
PbANKA_1016400	Pf3D7_1428200	Major facilitator superfamily domain-containing protein, putative (MFS5)	+	-	-	+	12/11	[-, -]	0.02				ND	Non-essential ^{dv}	Non-essential	
PbANKA_1422100	Pf3D7_0715800	Drug/metabolite transporter, putative (DMT1)	-	-	-	-	9/10	[-, -]	0.02				ND	Non-essential ^{dv}	Non-apicoplast/Non-essential	
PbANKA_0606900	Pf3D7_1208400	Amino acid transporter, putative	+	+	+	+	10/11	[-, -]	0.02				ND	Non-essential ^d	Non-apicoplast/Essential	

Gene IDs are given for both *P. berghei* and *P. falciparum* orthologues and *PlasmoDB* annotations are shown, distinguishing between putative membrane transporters and putative integral membrane proteins. If a gene name has been assigned, it is given in brackets after the annotation. Presence of a gene orthologue in *Toxoplasma gondii*, *Theileria*, *Babesia* and *Cryptosporidium* is indicated by '+' and absence is shown by '-'. ^aTransmembrane domains (TMD) were predicted in *P. falciparum* with TMHMM and TMpred. If there was a discrepancy, the TMHMM and strongest TMpred results are given (TMHMM/TMpred). ^bLocalisation was predicted with *PlasmoAP* and *PATS* in *P. falciparum*. ^c*P. berghei* normalised expression for rings (R), trophozoites (T), schizonts (S) and gametocytes (G) (Otto et al., 2014), was binned with thresholds on sample percentiles: 0-5% (Very low), 5-25% (Low), 25-75% (Moderate), 75-95% (High), 95-100% (Very high). For results: ND = no data, *localised in *P. falciparum*, ^dRijpma et al. (2016), ^econtradicted by Kenthirapalan et al. (2016), ^fconfirmed by Rijpma et al. (2016), ^gconfirmed by Kenthirapalan et al. (2016), ^hcontradicted by Rijpma et al. (2016), ⁱconfirmed by Bushell et al. (2017), ^jcontradicted by Bushell et al. (2017), ^kmutant displays significantly slow growth (Bushell et al., 2017). Each candidate was categorised by colour depending on blood stage essentiality and localisation results displayed in Figure 4.

but were included in the hope of extending the list of non-canonically targeted apicoplast membrane transporters. All shortlisted candidates are predicted to contain at least six and up to 17 TMDs and have orthologues in both *P. berghei* and *P. falciparum* (Table 1). Additionally, nine have *Toxoplasma gondii* orthologues, eight have orthologues in *Theileria*, six in *Babesia*, and 10 in *Cryptosporidium* (Table 1). Those with orthologues in *Cryptosporidium*, a model apicomplexan species that lacks an apicoplast (Zhu, Marchewka, & Keithly, 2000), were deprioritised. As a final criterion, we considered the level of blood stage expression of each candidate, namely, from very low to very high (Table 1). Shortlisting led us to include 27 candidate proteins, 20 of which are putative membrane transporters and seven of which are putative integral membrane proteins, not currently annotated as transporters (Table 1).

2.2 | Blood stage essentiality in rodent malaria

Initially, our genetic screen aimed to determine whether candidates were essential (parasites refractory to deletion) or non-essential (parasites survive deletion) during the blood stage of infection. This was achieved by attempting to delete candidate genes in *P. berghei*. Parasite lines were generated for 25 gene KO attempts, and PCR screening was performed to determine whether parasites lack the gene of interest or retain the wild-type (WT) locus (Figures 1a and S1). Nineteen candidates appeared to have successful integration of the KO vector, indicating that the genes of interest had been deleted (Figures 1a and S1). These 19 genes were considered to be non-essential for parasite survival at the blood stage. Six candidates were apparently essential for parasite survival at the blood stage as no PCR products detected integration of

the KO construct (Figure 1a). Instead, PCR screening generally showed that these parasites retained only the WT locus, suggesting that random integration had occurred and that the gene could not be deleted in surviving parasites (Figures 1a and S1). Only deletion of *PbANKA_0505500* yielded no parasites after three transfections with a KO construct. Therefore, *PbANKA_0505500* was deemed probably essential at the blood stage but PCRs could not be included in Figure 1a (Table 1).

We analysed a subset of the generated parasite lines, using Southern blotting to validate our genetic screen results. This confirmed our PCR results showing that *PbANKA_0614600* and *PbANKA_0942100* are probably essential (Figures S2-S4). Additionally, the candidate apicoplast membrane transporter, *PbANKA_0401200*, was reported to be refractory to deletion by Rijpma et al. (2016). We recovered parasites from only one of three transfections with the *PbANKA_0401200* KO construct, and although our PCR results indicated that integration had occurred (Figure S1), we set out to validate our positive result by Southern blot (Figures S5-S6). The results of the Southern blot were unclear for integration of the KO construct (Figure S6) so mRNA expression was examined by reverse transcriptase (RT)-PCR (Figure 1b,c). Three primer pairs within the *PbANKA_0401200* coding sequence amplified the expected WT product sizes from parasites carrying the *PbANKA_0401200* KO construct (Figure 1b,c). This suggested that an unusual integration occurred in *PbANKA_0401200* KO parasites, where the gene locus was modified but the gene is still expressed. We thus suggest that *PbANKA_0401200* is essential at the blood stage.

PlasmoGEM transfection vectors are expected to have low rates of random integration and episomally maintained vectors (Pfander et al.,






FIGURE 1 Candidate gene knockout PCR screen and reverse transcriptase-PCR in *Plasmodium berghei*. (a) PCR was performed on wild-type (WT) *PbANKA* and candidate gene knockout (KO) genomic DNA (gDNA) extracted from mixed population blood stage parasites. WT locus and integrant primers were used. PCR product bands were cropped from the correct well at the predicted product size of an ethidium bromide-stained agarose gel image. The *PbANKA_1364800* KO integrant primers span the entire KO construct with less than a 650 bp size difference between the WT and KO predicted products, so both the WT and KO products are observed in the cropped region of the agarose gel indicating that both the WT locus and integrated KO vector are present in the parasite population. (b) Three primer pairs were designed within the *PbANKA_0401200* coding sequence (CDS) to detect RNA expression, primers 1 (red), 2 (green), and 3 (blue). Primer positions and fragment sizes are shown on the gene schematic. RNA was extracted from clonal *PbANKA_0401200* KO parasites and reverse-transcribed into cDNA. (c) Tubulin primers were included and each primer pair was used to amplify WT *PbANKA* gDNA (positive controls) and *PbANKA_0401200* KO cDNA. No template control (NTC) and PCR reactions without reverse transcriptase (no RT) were used as negative controls. Reactions were electrophoresed, and PCR product bands were cropped from the correct well at the predicted product size of an ethidium bromide-stained agarose gel image. Primer type is given on left and sample type is given above

(b)



(c)



2011). However, in our experimental system, growth of parasites retaining the WT locus was common, indicating that many *Plasmo*GEM KO vectors can experience some random integration.

2.3 | Protein expression and apicoplast localisation

Sixteen candidate genes were HA-tagged for localisation experiments in *P. berghei*. PCR screening confirmed that all parasite lines contain the HA-tag (TAG) vector (Figure S7) and expression of the tagged protein was confirmed by Western blot (Figure 2a). Thirteen candidates had bands of the appropriate mass congruent with gene models (Figure 2a), and three (*PbANKA_0942100*, *PbANKA_0410500*, and *PbANKA_0916000*) likely suffer from electrophoresis anomalies common to membrane proteins (Kaur & Bachhawat, 2009). *PbANKA_0809500* TAG protein could not be detected in blood stage parasites (data not shown), which have low expression of the gene (Table 1), so protein was extracted from sporozoite parasites where expression was higher. Particularly faint signal was observed for *PbANKA_0417100* (Figure 2a), which is lowly expressed during the blood stages (Table 1). Tagged parasite lines were also generated in *P. falciparum*. *Pf3D7_1145500*-GFP (*PbANKA_0903500* orthologue)

had two GFP bands that were smaller than the predicted mass; the smallest may be dissociated GFP (Figure 2b). Finally, *Pf3D7_0716900-glmS* (*PfDMT2-glmS*), *Pf3D7_0302600-glmS* (*PfABC4-glmS*), and *Pf3D7_0302600-HA* (*PfABC4-HA*) had HA bands at the predicted masses (Figures 2c and S8).

Immunofluorescence assays (IFAs) were performed for all tagged candidate genes. Seven candidates co-localised with the apicoplast marker, ACP (Figure 3a,b). *PbANKA_0809500*, *PbANKA_0401200*, *PbANKA_0505500*, and *Pf3D7_1145500* were all predicted to have apicoplast targeting leader sequences whereas *PbANKA_1103600*, *PbANKA_1304700*, and *PfDMT2* were not predicted to contain leader sequences (Figure 3a,b and Table 1). Another seven candidates localised to non-apicoplast structures within the parasite (Figure 3d). Four candidates had no observable immunofluorescence signal at the blood stage so could not be localised in this life cycle stage: *PbANKA_0942100*, *PbANKA_0417100*, *PbANKA_1446100*, and *PbANKA_0602400* (data not shown). Life cycle analysis of two candidates (*PbANKA_1103600* and *PbANKA_0942100*) revealed that *PbANKA_1103600* TAG was expressed and localised to the apicoplast in midgut oocysts, salivary gland sporozoites, and *in vitro* liver cell stage parasites (Figure 3c). No signal was observed for *PbANKA_0942100*




FIGURE 2 Tagged candidate protein expression and *Pf3D7_0716900-glmS* knockdown. (a) Western blot analysis was performed on each HA-tagged (TAG) candidate in *Plasmodium berghei*. Parasite protein was extracted and separated by SDS-PAGE, transferred to a membrane, and visualised by probing with rat anti-HA primary and anti-rat HRP secondary antibodies. Protein band masses are shown by a standard marker (left). Parasite protein was extracted during the blood stage, except for *PbANKA_0809500* TAG, which was taken from sporozoites. (b) *Pf3D7_1145500*-GFP (ABC3) blood stage expression. Protein was probed with mouse anti-GFP primary and anti-mouse HRP secondary antibodies. Western blots were also performed once on protein extracted from the following sorbitol-synchronised parasites over 120 hr: (c) *Pf3D7_0716900-glmS* (DMT2-*glmS* clone B11) without glucosamine (GlcN) and (d) DMT2-*glmS* clone B11 with GlcN. Molecular mass markers are shown on left and antibodies are given on right. Anti-HA was used to monitor DMT2-*glmS* expression and anti-BiP as a protein loading control. Wild-type (WT) 3D7 protein was included as a negative control for non-specific antibody binding. To quantify protein expression, the data were normalised to BiP by calculating the ratio of HA to BiP signal (e) to compare DMT2-*glmS* expression with and without GlcN




FIGURE 3 Immunolocalisation of putative membrane proteins in *Plasmodium*. (a) *Plasmodium berghei* and *Plasmodium falciparum* (PfDMT2-*glmS* clone D6, PfABCB4-HA clone G3, and PfABCB4-*glmS* clone F11) candidate proteins were HA-tagged and probed with rat anti-HA primary and anti-rat 488 secondary antibodies (green). The apicoplast was probed with rabbit anti-ACP primary and anti-rabbit 546 secondary antibodies (red) and nuclei were stained with Hoechst (blue). Channels were merged with a transmission image (right) showing the location within the parasite. All candidates were localised within red blood cell stage parasites except *PbANKA_0809500*, which was localised in a sporozoite. Scale bars are 2 μm. (b) Pf3D7_1145500-GFP was localised in an intraerythrocytic parasite probed with mouse anti-GFP primary and anti-mouse 488 secondary antibodies (green; scale bar is 2 μm). (c) *PbANKA_1103600* TAG parasites were localised in oocyst, sporozoite, and *in vitro* liver cell stage parasites. Scale bars are 5 μm. (d) Seven candidates were also localised to non-apicoplast structures within intraerythrocytic parasites (scale bars are 2 μm)

TAG parasites at any life cycle stage so its localisation remains unknown (data not shown).

The results of the screen are summarised in Figure 4, highlighting the essentiality of the candidates and whether they are localised to the apicoplast. The characteristics of each candidate gene are represented in Table 1 by colour-coded categories based on their location in the Venn diagram (Figure 4).

2.4 | Knockdown of essential apicoplast putative membrane transporters in human malaria

Two candidates, identified as blood stage essential in the *P. berghei* genetic screen (*PbANKA_0401200* and *PbANKA_0614600*: *PbABCB4* and *PbDMT2*, respectively), were followed up with conditional knockdowns of orthologues in the human malaria parasite, *P. falciparum* (*Pf3D7_0302600* and *Pf3D7_0716900*: *PfABCB4* and *PfDMT2*, respectively). Glucosamine (GlcN)-induced *glmS* ribozyme knockdowns (Prommana et al., 2013) were generated and clonal integrant, WR99210 (WR)-resistant, parasites were obtained (Figures 5 and S9). The highest concentration of GlcN that allowed normal growth of the WT 3D7 parental line and a line carrying an HA-tagged protein targeted to the apicoplast (*PfABCB4-HA*) is 2.5 mM GlcN (Figure S10), so this concentration was selected for knockdown of transcripts in the *glmS* lines.

Localisation of *PfDMT2-glmS*, *PfABCB4-glmS*, and *PfABCB4-HA* confirmed the predicted apicoplast localisations and that the HA-tag




FIGURE 4 Screening results for candidate apicoplast membrane proteins in *Plasmodium*. Blood stage essentiality (Essential or Non-essential) and localisation (Apicoplast or Non-apicoplast) data were collected for 27 candidates. As shown in Table 1, each candidate was placed into one of the following categories: Essential, Apicoplast/Essential, Apicoplast, Apicoplast/Non-essential, Non-essential, Non-apicoplast/Non-essential, Non-apicoplast or Non-apicoplast/Essential. Proteins for which gene deletion or localisation data were not available are presented in a single category (Essential, Apicoplast, Non-essential, or Non-apicoplast)

Gene construct	WT gDNA		Transfectant gDNA	
	WT locus	Integrand	WT locus	Integrand
<i>Pf3D7_0302600-HA</i>				
<i>Pf3D7_0716900-glmS</i>				

FIGURE 5 Candidate gene PCR screen in *Plasmodium falciparum*. PCR was performed on wild-type (WT) 3D7, *Pf3D7_0302600-HA* (clone G3), and *Pf3D7_0716900-glmS* (clone B11) genomic DNA (gDNA) extracted from blood stage parasites. WT locus and integrant primers were used. PCR product bands were cropped from the correct well at the predicted product size of an ethidium bromide-stained agarose gel image

and *glmS* additions do not interfere with targeting (Figure 3a). Western blot analysis of *PfDMT2-glmS* parasites grown with and without GlcN confirmed an efficient knockdown of the putative transporter (Figure 2c,e). This knockdown trend was also observed in a different clonal line of *PfDMT2-glmS* parasites (Figure S11). It is noteworthy that expression of *PfDMT2-glmS* (without the addition of GlcN) fluctuates across the asexual cycle, with lowest expression in the merozoite/ring stage (0, 48, and 96 hr; Figure 2c). Nevertheless, addition of GlcN dramatically reduces the amount of *PfDMT2* protein (Figures 2d,e and S11). In contrast, the addition of GlcN to *PfABCB4-glmS* parasites did not substantially reduce protein levels nor did it impede growth (Figures S10 and S12). Therefore, it was not possible to conclude if *PfABCB4* is essential at the blood stage.

2.5 | *PfDMT2* knockdown is lethal but can be rescued with IPP supplementation

PfDMT2-glmS parasites were grown with different combinations of 2.5 mM GlcN and/or 200 μ M IPP to determine whether *PfDMT2* knockdown abrogates growth and whether a growth phenotype can be rescued by supplying exogenous IPP (Figure 6). As expected, IPP alone had no effect on the growth or morphology of *PfDMT2-glmS* parasites in a 6-day growth trial (Figure 6). Addition of GlcN to control parasites with IPP supplementation also had no effect on growth (Figure 6). In contrast, different clonal lines of *PfDMT2-glmS* parasites exposed to GlcN replicated normally in the first 48 hr but then failed to grow thereafter, with few healthy parasites visible after 6 days (Figures 6 and S13a–b). Growth of these knockdown parasites was restored when supplemented with IPP (Figures 6 and S13a–b), suggesting an apicoplast specific function for *PfDMT2*. Western blot analysis confirmed that *PfDMT2* protein expression was knocked down in these IPP rescued parasites (Figure S13c–d).

The effects of GlcN treatment are reversible as long as parasites remain viable (Prommana et al., 2013). *PfDMT2* knockdown parasites could recover when GlcN was removed after 12 days of treatment (Figure S13). In contrast, IPP rescued knockdown parasites could not be recovered when GlcN and IPP were removed (Figures 6 and S13a–b), suggesting that the apicoplast was irreversibly compromised in *PfDMT2* knockdown parasites rescued with IPP. It should also be noted that with prolonged exposure to GlcN, a small subpopulation of knockdown parasites became insensitive to the treatment. Parasites




FIGURE 6 *Pf3D7_0716900* knockdown IPP supplementation growth assay and parasite morphology. In one replicate, sorbitol-synchronised *Pf3D7_0716900-glmS* (DMT2-*glmS* clone B11) and *Pf3D7_0302600*-HA (ABC4-HA clone G3) control parasites were grown for up to 12 days with or without IPP and glucosamine (GlcN). (a) Treatment timelines for each culture are shown in the colour-coded table. As controls, HA parasites were grown with IPP and GlcN (+IPP+GlcN), and *glmS* parasites were grown without IPP and GlcN (-IPP-GlcN) for 6 days. On Day 6, cultures were discontinued, continued with the same treatment, or continued with a different treatment. Colour links a continued culture with the original culture (cultures coloured light blue, purple, and green, all originate from the same +IPP+GlcN culture coloured dark blue). Growth was monitored by daily blood smears, and parasitaemia was determined by calculating the percentage of infected red blood cells. Parasite growth is shown in Figure 6b. Dotted vertical lines on the graph every 2 days indicate when the cultures were subbed. "x" indicates when a culture was discontinued. (c) Parasite morphology was monitored by daily blood smears

could be recovered after 14 days in culture with GlcN, after which *PfDMT2* expression was detected (Figure S13).

2.6 | Rescued *PfDMT2* knockdown parasites are apicoplast-minus

To test whether knocking down *PfDMT2* resulted in loss of the apicoplast, we used real-time quantitative PCR to assess the impact of the *PfDMT2* knockdown on the apicoplast genome (Figure 7). By assessing the ratio of a single copy apicoplast gene to a single copy nuclear gene, and including a mitochondrial gene as a control, we measured the impact of GlcN and IPP on the apicoplast of *PfDMT2-glmS* parasites across three 48-hr red blood cell life cycles (Figure 7). In the absence of IPP and GlcN, both *PfDMT2-glmS* and control parasites

retain the apicoplast genome (Figure 7). In contrast, in *PfDMT2-glmS* parasites exposed to GlcN but rescued with IPP, there was no evidence of the apicoplast genome after three or six 48-hr life cycles (Figures 7 and S14). Apicoplast loss in these parasites was confirmed by IFA with no defined apicoplast structure visible in *PfDMT2-glmS* parasites treated with IPP and GlcN (Figure S15).

3 | DISCUSSION

Membrane transporters have good drug target potential (Kirk, 2004; Kirk & Lehane, 2014; Krishna, Webb, & Woodrow, 2001) so the *Plasmodium* transportome is a vital area of malaria research (Kirk & Lehane, 2014; Krishna et al., 2001). However, there is a lack of biological data




FIGURE 7 Organellar DNA in *Pf3D7_0716900* knockdown IPP rescued parasites. The ratio of mitochondrion and apicoplast DNA to nuclear DNA in IPP rescued parasites relative to wild-type (WT) parasites was measured by real-time PCR. Genomic DNA was extracted from WT 3D7 parasites, *Pf3D7_0716900-glmS* (DMT2-*glmS* clone B11) parasites growing without treatment (-IPP-GlcN), and with IPP and glucosamine (GlcN) for 12 days (+IPP+GlcN). *Pf3D7_0302600-HA* (ABCB4-HA clone G3) parasites growing without treatment (-IPP-GlcN) were included as a positive control. Reactions were performed in triplicate and the organellar to nuclear DNA (1.0) ratio was normalised relative to WT levels

for membrane transporters in *Plasmodium*, particularly for those on intracellular membranes (Kirk, 2004; Kirk & Lehane, 2014; Krishna et al., 2001). Only two apicoplast membrane transporters have been characterised to date (Mullin et al., 2006). It continues to be crucial to understand how molecules pass across the apicoplast membranes to fully understand *Plasmodium* biology and potentially offer novel drug targets. We set out to expand our understanding of apicoplast membrane transporters and their potential as drug targets by undertaking a medium throughput genetic screen addressing two central questions: Which proteins are essential for parasite survival at the blood stage, and which are localised to the apicoplast?

Five putative membrane transporters and three putative integral membrane proteins were identified as apparently essential at the *P. berghei* blood stage, flagging them as potentially good drug targets worthy of further characterisation. Two of these putative membrane transporters, *PbANKA_0614600* (DMT2) and *PbANKA_0401200* (ABCB4), and one of the putative integral membrane proteins, *PbANKA_0505500*, were apicoplast-localised. *PfDMT2* is a putative drug/metabolite transporter. Knockdown of *PfDMT2* prevents parasites from replicating in the second cycle; a phenotype reminiscent of the “delayed death” response to apicoplast-targeting drugs described in *Plasmodium* and other apicomplexan parasites (Fichera, Bhopale, & Roos, 1995; Goodman, Su, & McFadden, 2007). Parasites treated with delayed death drugs can be rescued in culture by the addition of IPP, the only essential metabolic product of the apicoplast during the red blood cell stage (Yeh & DeRisi, 2011). Here, we showed that the lethality of the *PfDMT2* knockdown phenotype is completely reversed by addition of IPP. This allowed us to conclude that abatement of *PfDMT2* disrupts apicoplast function, as confirmed by the absence of the apicoplast genome and the lack of a microscopically identifiable apicoplast organelle in knockdown parasites rescued with IPP supplementation. Unfortunately, an efficient knockdown of *PfABCB4* could not be achieved with our system. This appears to be one of the limitations of this inducible knockdown strategy and highlights the importance of trialling a number of different approaches to disrupt

an essential candidate gene. The knockdown phenotype of *PbANKA_0505500* remains to be tested.

On the basis of phylogenetic data showing the absence of a DMT2 orthologue in *Cryptosporidium* and the localisation of *PbDMT2* to an unknown intracellular structure (Kenthirapalan et al., 2016), Weiner and Kooij (2016) proposed that DMT2 might be an apicoplast-localised transport protein perhaps involved in IPP transport or the import of iron or sulfur for the iron-sulfur cluster biosynthesis pathway. Our analysis suggests that *PfDMT2* has a function in apicoplast maintenance rather than being solely an IPP transporter. Treatment of parasites with drugs disrupting housekeeping functions under IPP supplementation results in apicoplast loss (Yeh & DeRisi, 2011), although disruption of apicoplast IPP synthesis with IPP supplementation leaves the apicoplast intact (Gisselberg et al., 2013). By extension, disrupting an apicoplast housekeeping transporter while rescuing it with IPP should result in loss of the apicoplast through lack of a crucial biogenesis function. Conversely, the apicoplast should remain intact under IPP supplementation if the only role of the protein knocked down is IPP export. This assumes that a block in IPP export, and a consequent accumulation of IPP, is not toxic. If IPP build-up is toxic, disrupting an IPP exporter could result in a similar phenotype to targeting an apicoplast housekeeping gene. Our initial finding that *PfDMT2* is essential for the maintenance of the apicoplast shows that *PfDMT2* may not exclusively be an IPP exporter but likely plays a different and/or additional role in apicoplast function. It would be premature to totally dismiss *PfDMT2* as a candidate IPP transporter that also has other roles in apicoplast metabolism, but further work is clearly required to confirm its biological role.

One important consideration when screening for *Plasmodium* apicoplast membrane transporters is the potential exclusion of candidates based on the absence of predicted targeting motifs. Current prediction tools (Foth et al., 2003; Zuegge, Ralph, Schmuker, McFadden, & Schneider, 2001) are designed to predict the probability of a *P. falciparum* protein containing a canonical bipartite leader sequence. *PfoTPT*, one of the first apicoplast membrane transporters characterised and localised to the outer membrane, does not contain a leader (Mullin et al., 2006) and was not predicted to be apicoplast-localised. The targeting information required for the correct localisation of this type of membrane protein remains largely unexplored, in part because of a lack of confirmed, leaderless proteins to include in analyses. The only confirmed targeting information for these leaderless proteins is the presence of a tyrosine in the N-terminal region of the *Toxoplasma* orthologue of oTPT (DeRocher, Karnataki, Vaney, & Parsons, 2012), and we recently established that an N-terminal tyrosine residue is necessary but not sufficient for the apicoplast targeting of *PfoTPT* (Lim, Sayers, Goodman, & McFadden, 2016).

A number of leaderless candidate membrane proteins were included in our genetic screen with the hope of identifying further leaderless apicoplast membrane transporters. This proved successful with the identification of three novel leaderless apicoplast putative membrane transporters: DMT2, *PbANKA_1103600* (ATP3), and *PbANKA_1304700* (MFS6). Intriguingly, protein alignments revealed that these novel leaderless apicoplast proteins contain conserved N-terminal tyrosines just upstream of, or within, the first TMD (Figure S16). These proteins provide a starting point for dissecting

the process of leaderless apicoplast targeting by determining the universality of the N-terminal tyrosine in apicoplast targeting and whether it is outer membrane specific.

In addition to the blood stage essential candidates identified here, we found 18 candidates to be non-essential for blood stage growth. Furthermore, Rijpma et al. (2016) determined that our candidate *PbANKA_0903500* (ABCB3) is not essential at the blood stage. Together, 70% of our candidate proteins could be deleted in blood stage *P. berghei* parasites. Although termed non-essential in this study, it is important to consider that parasite fitness was not measured so a number of these candidates may be required for normal growth and become essential when in competition with other parasites in the field. Four of these 19 non-essential candidates were apicoplast-localised in this study: three putative membrane transporters (ABCB3, ATP3, and MFS6) and one putative integral membrane protein (*PbANKA_0809500*). Our blood stage essentiality results are largely consistent with recent findings (Bushell et al., 2017; Kenthirapalan et al., 2016; Rijpma et al., 2016) and combining these gives a broader understanding of the make-up of the putative parasite and apicoplast transportomes. It is becoming apparent that a number of *Plasmodium* putative membrane transporters can be deleted in blood stage parasites, shifting focus to the essential roles of membrane transporters during the mosquito and liver stages.

Interestingly, there are some differences in our combined *Plasmodium* transportome essentiality data. *PbANKA_1364800* (ABCB6) was found to be essential at the blood stage when Rijpma et al. (2016) could not generate ABCB6 KO parasites in *P. berghei* or *P. falciparum*, and Bushell et al. (2017) deemed *PbABCB6* probably essential for blood stage growth. This is contrary to our results, where we deleted *PbABCB6* in blood stage parasites. Further, we were unable to detect

integrated *PbANKA_0107700* (ZIP1) KO blood stage parasites and deemed it probably essential. In contrast, Kenthirapalan et al. (2016) generated ZIP1 KO blood stage parasites that had a growth defect and could not infect mosquitoes. Later experiments also generated *PbZIP1* KO parasites that grew significantly slower during the blood stage (Bushell et al., 2017). Bushell et al. (2017) reported several other contrasting results that *PbANKA_1429300* and *PbABCB4* are dispensable, and *PbATP3* and *PbANKA_1446100* are essential for blood stage growth.

It is noteworthy that the recovery of KO parasites may depend on the mutagenesis system used and that growth defects can have different impacts depending on the assays used. Rijpma et al. (2016) also reported that *PbABCB3* KO parasites had a severe blood stage growth defect although *PfABCB3* KO parasites had no growth defect in asexual blood stage or mosquito stage parasites. The conflicting reports between *P. berghei* and *P. falciparum* ABCB3 orthologues are a reminder that although these species are often considered somewhat equivalent, they are different and require independent validation to determine whether a gene has the same role in both organisms.

It is important to consider blood stage redundancy before embarking on any targeted drug development strategy. The parasite undergoes remarkable morphological changes during its life cycle (Hall et al., 2005) so it should not be surprising that transportome proteins are switched on and off as the parasite changes between diverse host environments. It is vital to distinguish between membrane transporters that are essential for parasite growth at some stage (growth arrest phenotype) and membrane transporters that are likely redundant and completely dispensable (no growth phenotype at any stage). Life cycle studies will hopefully address the question of whether blood stage dispensable genes are essential




FIGURE 8 Novel apicoplast putative membrane proteins in *Plasmodium*. The two previously characterised apicoplast membrane transporters, iTPT and oTPT, are shown on the inner and outer membranes. Dependent on whether they have an apicoplast leader, the predicted positions of five novel apicoplast putative membrane transporters (orange), and two novel apicoplast putative integral membrane proteins (blue), are shown. Membrane proteins with a leader are predicted to localise to the inner apicoplast membrane, as iTPT does. Candidates without a leader are predicted to localise to the outer apicoplast membrane, as oTPT does

elsewhere. Genes essential in pre-erythrocytic or transmission stages are ideal candidates for transmission or prophylactic drugs, which are essential in world malaria control efforts to prevent disease spread and ultimately support eradication.

In summary, we have generated biological data for a number of *Plasmodium* putative membrane transporters and integral membrane proteins, including five apicoplast putative membrane transporters and two apicoplast putative integral membrane proteins. This study has vastly expanded our knowledge of what proteins reside in the apicoplast membranes and boosted the running total to nine membrane proteins (Figure 8). The identification of three novel leaderless apicoplast putative membrane transporters confirms the existence of a cohort of non-canonically targeted apicoplast membrane transporters and should prove useful in the search for novel apicoplast targeting mechanisms and reveal a great deal about apicoplast biology. Heterologous expression and transport assays will be vital in confirming any transporter roles and determining any substrate specificities of the three new apparently blood stage essential apicoplast potential membrane transporters identified here, one of which is not currently predicted to be a transporter. Defining the function of PfDMT2 in the apicoplast will be a major new insight. The *Plasmodium* apicoplast continues to be an attractive drug target that is unique from its mammalian host. Although there is still a lot to learn about the *Plasmodium* transportome, this work provides a platform for future studies to achieve a better understanding of apicoplast biology and identify novel molecular targets to treat or prevent malaria.

4 | EXPERIMENTAL PROCEDURES

4.1 | Candidate gene selection

Potential *Plasmodium* apicoplast membrane transporters were shortlisted from two lists: 80 *P. falciparum* putative transport proteins (Martin et al., 2005) and 392 predicted *P. falciparum* apicoplast proteins that contain multiple TMDs (Ralph et al., 2004). The lists were screened using the *Plasmodium* genome database (*PlasmoDB*) version 30 (Aurrecochea et al., 2009), and protein localisation predictions were performed with *PlasmoAP* (Foth et al., 2003) and PATS (Zuegge et al., 2001). Gene orthologues were obtained for each candidate from OrthoMCL (Li, Stoeckert, & Roos, 2003), and TMD predictions were generated by TMHMM version 2.0 (<http://www.cbs.dtu.dk/services/TMHMM/>) and TMPred (http://www.ch.embnet.org/software/TMPRED_form.html). Candidates with at least one prediction of six TMDs were selected. Although some candidate proteins with multiple TMDs may not be membrane transporters, they were included due to the difficulty in definitively predicting membrane protein structure from protein sequence. Finally, *P. berghei* blood stage expression data were obtained for all candidates (Otto et al., 2014) and binned with thresholds on sample percentiles.

4.2 | Maintenance of *P. berghei* and *P. falciparum*

All animal procedures and experiments were performed in agreement with the local Prevention of Cruelty to Animals legislation and the University of Melbourne Animal Ethics Committee guidelines under ethics

permits 1112043, 1212488, and 1413078. *P. berghei* ANKA (*PbANKA*) blood stage parasites were grown in 4- to 6-week-old Swiss Webster mice that were sourced from the Monash Animal Research Platform. All *P. falciparum* blood stage culturing experiments were performed with human red blood cells (Australian Red Cross Blood Service) and in agreement with the University of Melbourne Human Ethics Committee guidelines under the ethics permit 1647087. *P. falciparum* 3D7 and D10 strain parasites were maintained as previously described (Trager & Jensen, 1976) in 2% haematocrit in RPMI-Hepes (WEHI) supplemented with Albumax II (Gibco) and sodium bicarbonate.

4.3 | Transfection vectors

Twenty-three KO and 16 HA-tag (TAG) transfection vectors were sourced from *PlasmoGEM* (plasmogem.sanger.ac.uk; Table S1). Three candidate genes were predicted to be apicoplast-localised and did not have *PlasmoGEM* KO transfection vectors available at the time. Double crossover homologous recombination KO constructs were therefore made for *PbANKA_0942100*, *PbANKA_0401200*, and *PbANKA_0505500* (Figure S17a). Typical KO and tagging strategies for all candidates are outlined in Figure S17. Primers were used to generate homologous 5' and 3' gene specific flanks (Table S2). The two flanks were ligated into the intermediate pGEM-T Easy Vector (Promega) and sequenced by the Australian Genome Research Facility with 5'-atttagtgacactatag (SP6) and 5'-taatacagctcactataggg (T7) primers. DNA flanks were ligated into either side of the pLDC (fusion of mCherry to the DHFR in the pL0006 vector [Malaria Research and Reference Reagent Resource Center]) selectable marker, DHFR, with corresponding restriction enzyme sites. Single crossover *glmS* ribozyme knockdown and control HA constructs were then made for *Pf3D7_0302600* and *Pf3D7_0716900* (Figure S18) to HA-tag and induce protein knockdown. The primers used to generate each gene-specific flank are in Table S3. BglII and PstI were used to ligate each flank into *glmS* and HA transfection vectors (Elsworth et al., 2014). Final plasmid DNA was sequenced by the Australian Genome Research Facility with SP6, 5'-agctgcatatccctcag, 5'-tgacacacacacacattttac, 5'-tgtaaacgacgcccag (M13-forward), and 5'-tccaatgtcatgataaaagaa primers.

4.4 | Parasite transfection

Approximately 10 µg of *P. berghei* DNA was linearised by NotI (*PlasmoGEM* vectors) and EcoRI/HindIII (pLDC vectors), and electroporated into WT *PbANKA* schizonts with an Amaxa Nucleofector Device (Lonza), as previously described (Janse, Ramesar, & Waters, 2006). After 24 hr, pyrimethamine (TCI) was added to the mouse drinking water to a final concentration of 70 µg/ml. Mice were typically monitored for pyrimethamine-resistant parasites until Day 14 post infection. Candidate genes were considered to be probably essential at the blood stage if mice remained uninfected after 14 days. At least three biological replicates were performed in this case to confirm the negative result. Using the standard transfection protocol (Crabb & Cowman, 1996; Wu, Sifri, Lei, Su, & Wellem, 1995), approximately 100 µg of *Pf3D7_1145500*-GFP plasmid DNA (gift from Liting Lim) was electroporated into ring stage WT *P. falciparum* D10 strain

parasites and *Pf3D7_0302600-glmS*, *Pf3D7_0302600-HA*, and *Pf3D7_0716900-glmS* plasmid DNA into ring stage WT *P. falciparum* 3D7 strain parasites. On Day 2, 1 pM/ml WR (Sigma-Aldrich) was added. WR-resistant parasites were recovered after 15 to 30 days. To encourage the plasmid DNA to integrate into the parasite genome, parasites were cycled off WR twice, for 3 weeks at a time.

4.5 | Parasite genotyping

In general, clonal parasites were not required in the *P. berghei* screen and mixed parasite populations were analysed. However, a clonal population of *PbANKA_0401200* KO parasites was required for Southern blot and RT-PCR analyses. A clonal line was recovered after diluted parasites were inoculated into 10 naïve mice. Clonal populations of all *P. falciparum* parasite lines were recovered after diluting in 96-well plates. Pyrimethamine-resistant parasite populations were screened with PCR primers detecting the WT locus, successful integration, and presence of the transfection vector (Figure S17 and; Tables 4–5). PCR primers also detected the WT locus and successful integration of WR-resistant parasites (Figure S18 and Table S6). A Southern blot was performed on *PbANKA_0401200* KO clonal parasite and *PbANKA_0942100* KO and *PbANKA_0614600* KO parasite gDNA using the gene-specific 5' flank and DHFR sequences as probes. To generate digoxigenin-labelled (Roche) probes, *PbANKA_0942100* and *PbANKA_0401200* utilised the 5' flank cloning primers (Table S2) and *PbANKA_0614600* used 5' flank primers (5'-gcaatgcgttttgcttag and 5'-gctccaccgcaatttattc). A standard DHFR probe was also used (Figure S19). Additionally, RNA was extracted from *PbANKA_0401200* KO clonal parasites for cDNA synthesis with SuperScript III Reverse Transcriptase (Invitrogen). To determine whether *PbANKA_0401200* was expressed in KO parasites, primers were designed within the coding sequence for RT-PCR (Table S7).

4.6 | Generating pre-erythrocytic stage parasites

PbANKA_1103600, *PbANKA_0942100*, and *PbANKA_0809500* TAG parasite lines were used to infect approximately 100 naïve female *Anopheles stephensi* strain MR4 mosquitoes. Mosquito midgut oocysts were typically harvested from Day 9 post infection and salivary gland sporozoites from Day 20 post infection. Furthermore, human hepatoma HepG2 cells (ATCC) were grown (Hollingdale, Leland, & Schwartz, 1983) and infected with *PbANKA_1103600* and *PbANKA_0942100* TAG sporozoites.

4.7 | Western blot analysis

Saponin-isolated intraerythrocytic parasites were resuspended in reducing buffer and heated to 70 °C before analysis. For sporozoite protein, approximately 100,000 sporozoites were released from mosquito salivary glands to which reducing buffer was added before freezing. Protein samples were electrophoresed using the NuPAGE system (Thermo Fisher Scientific) and transferred from the gel to a 0.22 µm UltraCruz Nitrocellulose Pure Transfer Membrane (Santa Cruz Biotechnology) or a 0.45 µm polyvinyl difluoride membrane (Thermo Fisher Scientific). After blocking, membranes were incubated with a monoclonal rat anti-HA antibody (1:250; Roche), mouse anti-GFP antibody

(1:100; Roche), rat anti-BiP antibody (1:500; ATCC) or apicoplast marker acyl carrier protein (ACP) anti-serum, rabbit anti-ACP (1:250). After washing, membranes were incubated with goat anti-rat horseradish peroxidase-conjugated (HRP) antibody, goat anti-mouse HRP antibody, or goat anti-rabbit HRP antibody (1:1000; Thermo Fisher Scientific). Protein bands were detected with the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). In addition, *glmS* ribozyme knockdown and HA-tag control parasites were grown with or without GlcN and saponin-isolated at 0, 12, 24, 48, 72, 96, and 120 hr before analysing as above. To normalise Western blot expression data, the ratio of HA to BiP signal was calculated by determining the signal peak area of each lane on the Western blot using the gel analysis tool in Fiji (Schindelin et al., 2012).

4.8 | Immunofluorescence assays

Infected blood, diluted to 1% in RPMI-Hepes with sodium bicarbonate, was adhered to 0.5 mg/ml concanavalin A (conA, Type V; Sigma-Aldrich)-coated 1.5 coverslips (Leica) as described (McMillan et al., 2013). Cells were fixed with 4% paraformaldehyde, 0.005% to 0.0075% glutaraldehyde (Electron Microscopy Sciences) in 1X Dulbecco's Phosphate Buffered Saline (DPBS) for 20 min and permeabilised with 0.1% Triton X-100 (Fisher Scientific) in 1X DPBS for 10 min. After washing, non-specific labelling caused by glutaraldehyde was reduced by incubating cells in 0.1 mg/ml sodium borohydride (BDH Chemicals) in 1X DPBS for 5 min. Cells were washed before blocking in 3% bovine serum albumin (BSA; Sigma-Aldrich) in 1X DPBS. Primary antibodies, monoclonal rat anti-HA, mouse anti-GFP, and rabbit anti-ACP, were incubated with the cells before washing. Secondary antibodies, goat anti-rat Alexa Fluor 488, goat anti-mouse Alexa Fluor 488, and goat anti-rabbit Alexa Fluor 546 (1:5000; Thermo Fisher Scientific), were then added for incubation before washing. Hoechst 33342 (1:10,000; Thermo Fisher Scientific) was included in the first few washes. Cells were mounted with 0.01% DABCO (Sigma-Aldrich) in 50% glycerol and 1X DPBS. The same antibodies were used in the following pre-erythrocytic parasite IFAs.

Infected midguts were fixed in 4% paraformaldehyde in 1X DPBS for 1 hr. Blocking and permeabilisation were performed at 4 °C overnight in 0.25% Triton X-100 in 5% BSA. Midguts were incubated with primary antibodies for at least 4 hr with shaking before washing three times with 1X DPBS. Samples were then incubated in secondary antibodies for 2 hr on an orbital shaker and then left at 4 °C overnight. Midguts were washed three times with the second wash containing Hoechst. Finally, midguts were mounted with DAKO (Agilent). Sporozoites were added to 3% BSA-coated coverslips and incubated at 37 °C for up to 15 min. Sporozoites were fixed with 4% paraformaldehyde in 1X DPBS for 10 min and permeabilisation was achieved with 0.2% Triton X-100 in 1X DPBS for 20 min. Samples were incubated with primary antibodies for at least 1 hr, washed three times and then incubated with secondary antibodies for at least 1 hr. The antibody solution was washed away with one wash containing Hoechst. Again, samples were mounted with DAKO. Finally, infected *in vitro* liver cells were fixed with 4% paraformaldehyde for 20 min at 24, 48, and 63 hr post infection. Cells were washed before 0.1% Triton X-100 in 1X DPBS was added for 20 min for permeabilisation. After washing, 3%

BSA in 1X DPBS was added for 30 min before the liver cell-coated coverslips were placed on the primary antibodies for 1 hr. Coverslips were washed three times before being placed on secondary antibodies containing Hoechst for 1 hr. The coverslips were washed then mounted with DAKO. IFAs were imaged on an inverted Leica SP2 or Nikon A1R confocal microscope with a 63X oil immersion objective. Image brightness, contrast, and noise were adjusted in Fiji (Schindelin et al., 2012) when appropriate, and images were merged.

4.9 | Protein alignments

Gene orthologues and protein sequences were obtained from PlasmoDB and OrthoMCL (Aurrecochea et al., 2009; Li et al., 2003) and predicted TMD locations were generated by HMMTOP (Tusnády & Simon, 1998, 2001). Clustal Omega (1.2.2) Multiple Sequence Alignment (Sievers et al., 2011) was used to align gene orthologue protein sequences.

4.10 | *P. falciparum* growth assays

The fluorescence-based technique for drug trials in *P. falciparum* was used to determine the effect of GlcN (Sigma-Aldrich) on WT 3D7, ABCB4-HA, and ABCB4-*glmS* parasite growth (Smilkstein, Sriwilajaroen, Kelly, Wilairat, & Riscoe, 2004). Data were normalised to no drug and no parasite controls before a logarithmic drug curve was plotted with GraphPad Prism version 7.0b. For IPP supplementation, *PfDMT2-glmS* and control parasites were grown in 5 ml cultures for up to 18 days with different treatments of 2.5 mM GlcN and 200 μ M IPP (Yeh & DeRisi, 2011). Cultures were smeared every 24 hr, which were imaged with a Leica DM2500 microscope using a 40X objective and a Leica DC300F camera. A Giemsa-Counter plugin in Fiji (Schindelin et al., 2012) was used to count a minimum of 2000 red blood cells per sample. Parasites within the red blood cells were then manually counted to determine parasitaemia. Cultures were subbed to approximately 1% parasitaemia every 48 hr.

4.11 | Real-time PCR

Primers were designed to target genes in the mitochondrial, apicoplast, and nuclear genomes (Table S8), which were used to amplify DNA extracted from IPP supplemented and control parasites. A 2X KAPA SYBR FAST qPCR Master Mix (Universal; Kapa Biosystems) was used for real-time PCR reactions with the following conditions: 95 °C (3 min, 1 cycle), 95 °C (10 s), 60.2 °C (30 s, 40 cycles), and 60 to 95 °C (5 s, increasing 0.5 °C per hold). Every reaction was performed in triplicate and the quantification cycle (Cq) values were obtained for each. The relative quantification of gene expression, or the ratio of organellar to nuclear DNA relative to WT, was then calculated as previously described (Schmittgen & Livak, 2008).

ACKNOWLEDGEMENTS

We thank the PlasmoGEM team, particularly Ellen Bushell, at the Wellcome Trust Sanger Institute for the majority of the *P. berghei*

transfection vectors and Tania de Koning-Ward and Paul Gilson for the *P. falciparum* ribozyme knockdown and control HA-tag transfection vectors. Anton Cozijnsen and Liting Lim are thanked for their technical assistance, and the Australian Red Cross Blood Service is gratefully acknowledged for providing human red blood cells for culturing. Stuart Ralph is thanked for providing his list of putative apicoplast proteins, Lachlan Whitehead is acknowledged for creating the Giesma-Counter plugin for Fiji, and Daniele Muraro is thanked for his assistance with the analysis of published expression data. Claire Sayers was supported by a Melbourne Research Scholarship and the David Lachlan Hay Memorial Fund. This work was funded by an Australian Research Council Discovery Project (DP160104980), and National Health and Medical Research Council Program (637406) and Project (1106213) grants.

ORCID

Claire P. Sayers  <http://orcid.org/0000-0001-7103-4222>

Vanessa Mollard  <http://orcid.org/0000-0001-9222-8229>

Hayley D. Buchanan  <http://orcid.org/0000-0002-2764-1428>

Geoffrey I. McFadden  <http://orcid.org/0000-0002-5351-1627>

Christopher D. Goodman  <http://orcid.org/0000-0002-8923-7594>

REFERENCES

- Aurrecochea, C., Brestelli, J., Brunk, B. P., Dommer, J., Fischer, S., Gajria, B., ... Wang, H. (2009). PlasmoDB: a functional genomic database for malaria parasites. *Nucleic Acids Research*, 37(Database issue), D539–D543. <http://doi.org/10.1093/nar/gkn814>
- Banerjee, T., Jaijyan, D. K., Surolia, N., Singh, A. P., & Surolia, A. (2012). Apicoplast triose phosphate transporter (TPT) gene knockout is lethal for *Plasmodium*. *Molecular and Biochemical Parasitology*, 186(1), 44–50. <http://doi.org/10.1016/j.molbiopara.2012.09.008>
- Bölter, B., & Soll, J. (2001). Ion channels in the outer membranes of chloroplasts and mitochondria: Open doors or regulated gates? *The EMBO Journal*, 20(5), 935–940. <http://doi.org/10.1093/emboj/20.5.935>
- Brooks, C. F., Johnsen, H., van Dooren, G. G., Muthalagi, M., Lin, S. S., Bohne, W., ... Striepen, B. (2010). The *Toxoplasma* apicoplast phosphate translocator links cytosolic and apicoplast metabolism and is essential for parasite survival. *Cell Host & Microbe*, 7(1), 62–73. <http://doi.org/10.1016/j.chom.2009.12.002>
- Bushell, E., Gomes, A. R., Sanderson, T., Anar, B., Girling, G., Herd, C., ... Billker, O. (2017). Functional profiling of a *Plasmodium* genome reveals an abundance of essential genes. *Cell*, 170(2), 260–272. <http://doi.org/10.1016/j.cell.2017.06.030>
- Crabb, B. S., & Cowman, A. F. (1996). Characterization of promoters and stable transfection by homologous and nonhomologous recombination in *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences of the United States of America*, 93(14), 7289–7294.
- DeRocher, A. E., Karnataki, A., Vaney, P., & Parsons, M. (2012). Apicoplast targeting of a *Toxoplasma gondii* transmembrane protein requires a cytosolic tyrosine-based motif. *Traffic*, 13(5), 694–704. <http://doi.org/10.1111/j.1600-0854.2012.01335.x>
- Elsworth, B., Matthews, K., Nie, C. Q., Kalanon, M., Charnaud, S. C., Sanders, P. R., ... de Koning-Ward, T. F. (2014). PTEX is an essential nexus for protein export in malaria parasites. *Nature*, 511(7511), 587–591. <http://doi.org/10.1038/nature13555>
- Fichera, M. E., Bhopale, M. K., & Roos, D. S. (1995). *In vitro* assays elucidate peculiar kinetics of clindamycin action against *Toxoplasma gondii*. *Antimicrobial Agents and Chemotherapy*, 39(7), 1530–1537.
- Fischer, K. (2011). The import and export business in plastids: Transport processes across the inner envelope membrane. *Plant Physiology*, 155(4), 1511–1519. <http://doi.org/10.1104/pp.110.170241>

- Foth, B. J., Ralph, S. A., Tonkin, C. J., Struck, N. S., Fraunholz, M. J., Roos, D. S., ... McFadden, G. I. (2003). Dissecting apicoplast targeting in the malaria parasite *Plasmodium falciparum*. *Science*, 299(5607), 705–708. <http://doi.org/10.1126/science.1078599>
- Gisselberg, J. E., Dellibovi-Ragheb, T. A., Matthews, K. A., Bosch, G., & Prigge, S. T. (2013). The Suf iron-sulfur cluster synthesis pathway is required for apicoplast maintenance in malaria parasites. *PLoS Pathogens*, 9(9), e1003655. <http://doi.org/10.1371/journal.ppat.1003655.s009>
- Golldack, A., Henke, B., Bergmann, B., Wiechert, M., Erler, H., Blancke Soares, A., ... Beitz, E. (2017). Substrate-analogous inhibitors exert anti-malarial action by targeting the *Plasmodium* lactate transporter PfFNT at nanomolar scale. *PLoS Pathogens*, 13(2). e1006172. <http://doi.org/10.1371/journal.ppat.1006172>
- Gomes, A. R., Bushell, E., Schwach, F., Girling, G., Anar, B., Quail, M. A., ... Billker, O. (2015). A genome-scale vector resource enables high-throughput reverse genetic screening in a malaria parasite. *Cell Host & Microbe*, 17(3), 404–413. <http://doi.org/10.1016/j.chom.2015.01.014>
- Goodman, C. D., Su, V., & McFadden, G. I. (2007). The effects of anti-bacterials on the malaria parasite *Plasmodium falciparum*. *Molecular and Biochemical Parasitology*, 152(2), 181–191. <http://doi.org/10.1016/j.molbiopara.2007.01.005>
- Hall, N., Karras, M., Raine, J. D., Carlton, J. M., Kooij, T. W. A., Berriman, M., ... Sinden, R. E. (2005). A comprehensive survey of the *Plasmodium* life cycle by genomic, transcriptomic, and proteomic analyses. *Science*, 307(5706), 82–86. <http://doi.org/10.1126/science.1103717>
- Hollingdale, M. R., Leland, P., & Schwartz, A. L. (1983). *In vitro* cultivation of the exoerythrocytic stage of *Plasmodium berghei* in a hepatoma cell line. *The American Journal of Tropical Medicine and Hygiene*, 32(4), 682–684.
- Janse, C. J., Ramesar, J., & Waters, A. P. (2006). High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite *Plasmodium berghei*. *Nature Protocols*, 1(1), 346–356. <http://doi.org/10.1038/nprot.2006.53>
- Joët, T., Eckstein-Ludwig, U., Morin, C., & Krishna, S. (2003). Validation of the hexose transporter of *Plasmodium falciparum* as a novel drug target. *Proceedings of the National Academy of Sciences*, 100(13), 7476–7479. <http://doi.org/10.1073/pnas.1330865100>
- Joët, T., & Krishna, S. (2004). The hexose transporter of *Plasmodium falciparum* is a worthy drug target. *Acta Tropica*, 89(3), 371–374. <http://doi.org/10.1016/j.actatropica.2003.11.003>
- Kaur, J., & Bachhawat, A. K. (2009). A modified Western blot protocol for enhanced sensitivity in the detection of a membrane protein. *Analytical Biochemistry*, 384(2), 348–349. <http://doi.org/10.1016/j.ab.2008.10.005>
- Ke, H., Sigala, P. A., Miura, K., Morrissey, J. M., Mather, M. W., Crowley, J. R., ... Vaidya, A. B. (2014). The heme biosynthesis pathway is essential for *Plasmodium falciparum* development in mosquito stage but not in blood stages. *Journal of Biological Chemistry*, 289(50), 34827–34837. <http://doi.org/10.1074/jbc.M114.615831>
- Kenthirapalan, S., Waters, A. P., Matuschewski, K., & Kooij, T. W. A. (2016). Functional profiles of orphan membrane transporters in the life cycle of the malaria parasite. *Nature Communications*, 7(10519). <http://doi.org/10.1038/ncomms10519>
- Kirk, K. (2004). Channels and transporters as drug targets in the *Plasmodium*-infected erythrocyte. *Acta Tropica*, 89(3), 285–298. <http://doi.org/10.1016/j.actatropica.2003.10.002>
- Kirk, K., & Lehane, A. M. (2014). Membrane transport in the malaria parasite and its host erythrocyte. *Biochemical Journal*, 457(1), 1–18. <http://doi.org/10.1042/BJ20131007>
- Köhler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. J., ... Roos, D. S. (1997). A plastid of probable green algal origin in apicomplexan parasites. *Science*, 275(5305), 1485–1489. <http://doi.org/10.1126/science.275.5305.1485>
- Krishna, S., Webb, R., & Woodrow, C. (2001). Transport proteins of *Plasmodium falciparum*: Defining the limits of metabolism. *International Journal for Parasitology*, 31(12), 1331–1342.
- Krishna, S., Woodrow, C. J., Burchmore, R. J., Saliba, K. J., & Kirk, K. (2000). Hexose transport in asexual stages of *Plasmodium falciparum* and kinetoplastidae. *Parasitology Today*, 16(12), 516–521. [http://doi.org/10.1016/S0169-4758\(00\)01762-2](http://doi.org/10.1016/S0169-4758(00)01762-2)
- Lehane, A. M., Ridgway, M. C., Baker, E., & Kirk, K. (2014). Diverse chemotypes disrupt ion homeostasis in the malaria parasite. *Molecular Microbiology*, 94(2), 327–339. <http://doi.org/10.1111/mmi.12765>
- Li, L., Stoeckert, C. J. Jr., & Roos, D. S. (2003). OrthoMCL: Identification of ortholog groups for eukaryotic genomes. *Genome Research*, 13(9), 2178–2189. <http://doi.org/10.1101/gr.1224503>
- Lim, L., Linka, M., Mullin, K. A., Weber, A. P. M., & McFadden, G. I. (2010). The carbon and energy sources of the non-photosynthetic plastid in the malaria parasite. *FEBS Letters*, 584(3), 549–554. <http://doi.org/10.1016/j.febslet.2009.11.097>
- Lim, L., Sayers, C. P., Goodman, C. D., & McFadden, G. I. (2016). Targeting of a transporter to the outer apicoplast membrane in the human malaria parasite *Plasmodium falciparum*. *PLoS One*, 11(7), e0159603. <http://doi.org/10.1371/journal.pone.0159603.s002>
- Marchetti, R. V., Lehane, A. M., Shafik, S. H., Winterberg, M., Martin, R. E., & Kirk, K. (2015). A lactate and formate transporter in the intraerythrocytic malaria parasite, *Plasmodium falciparum*. *Nature Communications*, 6(6721). <http://doi.org/10.1038/ncomms7721>
- Martin, R. E., Ginsburg, H., & Kirk, K. (2009). Membrane transport proteins of the malaria parasite. *Molecular Microbiology*, 74(3), 519–528. <http://doi.org/10.1111/j.1365-2958.2009.06863.x>
- Martin, R. E., Henry, R. I., Abbey, J. L., Clements, J. D., & Kirk, K. (2005). The “permeome” of the malaria parasite: An overview of the membrane transport proteins of *Plasmodium falciparum*. *Genome Biology*, 6(3), R26. <http://doi.org/10.1186/gb-2005-6-3-r26>
- McFadden, G. I., Reith, M. E., Munholland, J., & Lang-Unnasch, N. (1996). Plastid in human parasites. *Nature*, 381(6582), 482. <http://doi.org/10.1038/381482a0>
- McFadden, G. I., & van Dooren, G. G. (2004). Evolution: Red algal genome affirms a common origin of all plastids. *Current Biology*, 14(13), R514–R516. <http://doi.org/10.1016/j.cub.2004.06.041>
- McMillan, P. J., Millet, C., Batinovic, S., Maiorca, M., Hanssen, E., Kenny, S., ... Tilley, L. (2013). Spatial and temporal mapping of the PfEMP1 export pathway in *Plasmodium falciparum*. *Cellular Microbiology*, 15(8), 1401–1418. <http://doi.org/10.1111/cmi.12125>
- Mullin, K. A., Lim, L., Ralph, S. A., Spurck, T. P., Handman, E., & McFadden, G. I. (2006). Membrane transporters in the relict plastid of malaria parasites. *Proceedings of the National Academy of Sciences*, 103(25), 9572–9577. <http://doi.org/10.1073/pnas.0602293103>
- Nagaraj, V. A., Sundaram, B., Varadarajan, N. M., Subramani, P. A., Kalappa, D. M., Ghosh, S. K., & Padmanaban, G. (2013). Malaria parasite-synthesized heme is essential in the mosquito and liver stages and complements host heme in the blood stages of infection. *PLoS Pathogens*, 9(8). e1003522. <http://doi.org/10.1371/journal.ppat.1003522>
- Otto, T. D., Böhme, U., Jackson, A. P., Hunt, M., Franke-Fayard, B., Hoesijmakers, W. A. M., ... Janse, C. J. (2014). A comprehensive evaluation of rodent malaria parasite genomes and gene expression. *BMC Biology*, 12(86). <http://doi.org/10.1186/s12915-014-0086-0>
- Pfander, C., Anar, B., Brochet, M., Rayner, J. C., & Billker, O. (2012). Recombination-mediated genetic engineering of *Plasmodium berghei* DNA. In *Malaria: Methods and protocols* (Vol. 923) (pp. 127–138). Totowa, NJ: New York, Humana, Springer distributor. http://doi.org/10.1007/978-1-62703-026-7_8
- Pfander, C., Anar, B., Schwach, F., Otto, T. D., Brochet, M., Volkman, K., ... Billker, O. (2011). A scalable pipeline for highly effective genetic modification of a malaria parasite. *Nature Methods*, 8(12), 1078–1082. <http://doi.org/10.1038/nmeth.1742>
- Pick, T. R., & Weber, A. P. M. (2014). Unknown components of the plastidial permeome. *Frontiers in Plant Science*, 5(410). <http://doi.org/10.3389/fpls.2014.00410>
- Prommana, P., Uthaipibull, C., Wongsombat, C., Kamchonwongpaisan, S., Yuthavong, Y., Knuepfer, E., ... Shaw, P. J. (2013). Inducible knockdown

- of *Plasmodium* gene expression using the *glmS* ribozyme. *PLoS One*, 8(8), e73783. <http://doi.org/10.1371/journal.pone.0073783>
- Ralph, S. A., van Dooren, G. G., Waller, R. F., Crawford, M. J., Fraunholz, M. J., Foth, B. J., ... McFadden, G. I. (2004). Metabolic maps and functions of the *Plasmodium falciparum* apicoplast. *Nature Reviews Microbiology*, 2(3), 203–216. <http://doi.org/10.1038/nrmicro843>
- Rathnapala, U. L., Goodman, C. D., & McFadden, G. I. (2017). A novel genetic technique in *Plasmodium berghei* allows liver stage analysis of genes required for mosquito stage development and demonstrates that de novo heme synthesis is essential for liver stage development in the malaria parasite. *PLoS Pathogens*, 13(6), e1006396. <http://doi.org/10.1371/journal.ppat.1006396>
- Rijpmans, S. R., van der Velden, M., Annoura, T., Matz, J. M., Kenthirapalan, S., Kooij, T. W. A., ... Koenderink, J. B. (2016). Vital and dispensable roles of *Plasmodium* multidrug resistance transporters during blood- and mosquito-stage development. *Molecular Microbiology*, 101(1), 78–91. <http://doi.org/10.1111/mmi.13373>
- Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., ... Diagana, T. T. (2010). Spiroindolones, a potent compound class for the treatment of malaria. *Science*, 329(5996), 1175–1180. <http://doi.org/10.1126/science.1193225>
- Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., ... Cardona, A. (2012). Fiji: An open source platform for biological image analysis. *Nature Methods*, 9(7), 676–682. <http://doi.org/10.1038/nmeth.2019>
- Schmittgen, T. D., & Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C_T method. *Nature Protocols*, 3(6), 1101–1108. <http://doi.org/10.1038/nprot.2008.73>
- Schwach, F., Bushell, E., Gomes, A. R., Anar, B., Girling, G., Herd, C., ... Billker, O. (2015). *PlasmoGEM*, a database supporting a community resource for large-scale experimental genetics in malaria parasites. *Nucleic Acids Research*, 43(Database issue), D1176–D1182. <http://doi.org/10.1093/nar/gku1143>
- Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., ... Higgins, D. G. (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular Systems Biology*, 7(539). <http://doi.org/10.1038/msb.2011.75>
- Smilkstein, M., Sriwilajaroen, N., Kelly, J. X., Wilairat, P., & Riscoe, M. (2004). Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrobial Agents and Chemotherapy*, 48(5), 1803–1806.
- Spillman, N. J., Allen, R. J. W., McNamara, C. W., Yeung, B. K. S., Winzeler, E. A., Diagana, T. T., & Kirk, K. (2013). Na^+ regulation in the malaria parasite *Plasmodium falciparum* involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. *Cell Host & Microbe*, 13(2), 227–237. <http://doi.org/10.1016/j.chom.2012.12.006>
- Trager, W., & Jensen, J. B. (1976). Human malaria parasites in continuous culture. *Science*, 193(4254), 673–675. <http://doi.org/10.1126/science.123395>
- Tusnády, G. E., & Simon, I. (1998). Principles governing amino acid composition of integral membrane proteins: Application to topology prediction. *Journal of Molecular Biology*, 283(2), 489–506. <http://doi.org/10.1006/jmbi.1998.2107>
- Tusnády, G. E., & Simon, I. (2001). The HMMTOP transmembrane topology prediction server. *Bioinformatics*, 17(9), 849–850.
- van Dooren, G. G., & Striepen, B. (2013). The algal past and parasite present of the apicoplast. *The Annual Review of Microbiology*, 67(1), 271–289. <http://doi.org/10.1146/annurev-micro-092412-155741>
- van Schaijk, B. C. L., Kumar, T. R. S., Vos, M. W., Richman, A., van Gemert, G.-J., Li, T., ... Vaughan, A. M. (2014). Type II fatty acid biosynthesis is essential for *Plasmodium falciparum* sporozoite development in the mid-gut of *Anopheles* mosquitoes. *Eukaryotic Cell*, 13(5), 550–559. <http://doi.org/10.1128/EC.00264-13>
- Weber, A. P. M., & Linka, N. (2011). Connecting the plastid: Transporters of the plastid envelope and their role in linking plastidial with cytosolic metabolism. *Annual Review of Plant Biology*, 62(1), 53–77. <http://doi.org/10.1146/annurev-arplant-042110-103903>
- Weiner, J. 3rd, & Kooij, T. W. A. (2016). Phylogenetic profiles of all membrane transport proteins of the malaria parasite highlight new drug targets. *Microbial Cell*, 3(10), 511–521. <http://doi.org/10.15698/mic2016.10.534>
- Woodrow, C. J., Penny, J. I., & Krishna, S. (1999). Intraerythrocytic *Plasmodium falciparum* expresses a high affinity facilitative hexose transporter. *Journal of Biological Chemistry*, 274(11), 7272–7277. <http://doi.org/10.1074/jbc.274.11.7272>
- Wu, Y., Sifri, C. D., Lei, H.-H., Su, X.-Z., & Wellems, T. E. (1995). Transfection of *Plasmodium falciparum* within human red blood cells. *Proceedings of the National Academy of Sciences of the United States of America*, 92(4), 973–977.
- Yeh, E., & DeRisi, J. L. (2011). Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage *Plasmodium falciparum*. *PLoS Biology*, 9(8), e1001138. <http://doi.org/10.1371/journal.pbio.1001138.s009>
- Yu, M., Kumar, T. R., Nkrumah, L. J., Coppi, A., Retzlaff, S., Li, C. D., ... Fidock, D. A. (2008). The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. *Cell Host & Microbe*, 4(6), 567–578. <http://doi.org/10.1016/j.chom.2008.11.001>
- Zhu, G., Marchewka, M. J., & Keithly, J. S. (2000). *Cryptosporidium parvum* appears to lack a plastid genome. *Microbiology*, 146(Pt 2), 315–321. <http://doi.org/10.1099/00221287-146-2-315>
- Zuegge, J., Ralph, S. A., Schmuker, M., McFadden, G. I., & Schneider, G. (2001). Deciphering apicoplast targeting signals—Feature extraction from nuclear-encoded precursors of *Plasmodium falciparum* apicoplast proteins. *Gene*, 280, 19–26.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Sayers CP, Mollard V, Buchanan HD, McFadden GI, Goodman CD. A genetic screen in rodent malaria parasites identifies five new apicoplast putative membrane transporters, one of which is essential in human malaria parasites. *Cellular Microbiology*. 2017;e12789. <https://doi.org/10.1111/cmi.12789>